GlassScriptPhysician profile
Leila C Morris
NPI 1760426696
$3,134.06
in general payments reported to CMS, 2019-2025
20 companies · $231 in 2025
The $231 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $181 · 2020: $385 · 2021: $424 · 2022: $386 · 2023: $977 · 2024: $551 · 2025: $231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,657 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $63.75 · Education: $32.27 · Travel and Lodging: $6.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,656.63 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $63.75 |
| Education | $32.27 |
| Travel and Lodging | $6.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $719.47 | 2019-2025 | Wegovy, Saxenda, Ozempic |
| Abbvie INC. | $519.35 | 2021-2024 | |
| Lilly USA, LLC | $462.61 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $287.49 | 2019-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $174.59 | 2019-2025 | |
| Glaxosmithkline, LLC. | $164.07 | 2021-2024 | Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $145.90 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $139.85 | 2019-2024 | Airsupra, Farxiga |
| Amarin Pharma, INC. | $130.95 | 2019-2021 | |
| Esperion Therapeutics, INC. | $102.71 | 2021-2025 | Nexletol |
| Novartis Pharmaceuticals Corporation | $61.86 | 2021-2023 | |
| Hologic Sales and Service, LLC | $40.84 | 2019-2025 | Aptima |
| Astellas Pharma US INC | $30.34 | 2024 | Veozah |
| Exact Sciences Corporation | $29.50 | 2024 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $27.87 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $25.30 | 2021 | |
| Xeris Pharmaceuticals, INC. | $22.59 | 2025 | Recorlev |
| Lucid Diagnostics INC. | $17.68 | 2022 | |
| Sanofi-Aventis U.S. LLC | $16.39 | 2020 | |
| Currax Pharmaceuticals LLC | $14.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leila Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.